Learn From the Experts About Collaborative Practice in the Management of Cancer Patients
Gain insights and clinical knowledge on the science of new targeted therapies and immunotherapies for the treatment of hematologic malignancies. Learn how to manage the side effects and other clinical issues associated with these new treatments in a case-based, informal educational setting.
Upon completion of this activity, participants will be able to:
- Identify the mechanism of action for novel agents used for the treatment of hematological malignancies including Multiple Myeloma, CLL, Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL).
- List monitoring parameters for toxicities associated with newer agents used to treat multiple myeloma, CLL, HL, and NHL.
- Describe the signs of early and serious toxicity that providers and patients need to be aware of when initiating therapy with new agents for multiple myeloma, CLL, HL and NHL.
- Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings.
- Anticipate and identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome.
- Identify strategies for encouraging patient adherence to oral therapeutics.
- Discuss the pivotal role and necessary expertise of the AP as a vital part of the inter-professional oncology/hematology team.